394 related articles for article (PubMed ID: 33253313)
1. Anlotinib for refractory advanced non-small-cell lung cancer: A systematic review and meta-analysis.
Yu G; Shen Y; Xu X; Zhong F
PLoS One; 2020; 15(11):e0242982. PubMed ID: 33253313
[TBL] [Abstract][Full Text] [Related]
2. Response to first-line treatment predicts progression-free survival benefit of small-cell lung cancer patients treated with anlotinib.
Qin B; Xin L; Hou Q; Yang B; Zhang J; Qi X; Wei Y; Hu Y; Xiong Q
Cancer Med; 2021 Jun; 10(12):3896-3904. PubMed ID: 33960145
[TBL] [Abstract][Full Text] [Related]
3. China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy.
Zhou M; Chen X; Zhang H; Xia L; Tong X; Zou L; Hao R; Pan J; Zhao X; Chen D; Song Y; Qi Y; Tang L; Liu Z; Gao R; Shi Y; Yang Z
Cancer Commun (Lond); 2019 Jun; 39(1):36. PubMed ID: 31221221
[TBL] [Abstract][Full Text] [Related]
4. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302).
Han B; Li K; Zhao Y; Li B; Cheng Y; Zhou J; Lu Y; Shi Y; Wang Z; Jiang L; Luo Y; Zhang Y; Huang C; Li Q; Wu G
Br J Cancer; 2018 Mar; 118(5):654-661. PubMed ID: 29438373
[TBL] [Abstract][Full Text] [Related]
5. Hand-foot syndrome and survival in patients with advanced non-small-cell lung cancer receiving anlotinib: a subgroup analysis of data from the ALTER 0303 study.
Nan X; Xie C; Zhu Q; Zhang J; Fu S; Han X; Zhang Q; Han B; Liu J
Int J Clin Oncol; 2020 Aug; 25(8):1492-1498. PubMed ID: 32447474
[TBL] [Abstract][Full Text] [Related]
6. Salvage treatment with anlotinib for advanced non-small cell lung cancer.
Wu D; Nie J; Dai L; Hu W; Zhang J; Chen X; Ma X; Tian G; Han J; Han S; Long J; Wang Y; Zhang Z; Fang J
Thorac Cancer; 2019 Jul; 10(7):1590-1596. PubMed ID: 31183998
[TBL] [Abstract][Full Text] [Related]
7. Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib.
Tang M; Song C; Zhang Y; Xu X; Wang C; Zhang Z; Chen T
Lipids Health Dis; 2021 Nov; 20(1):165. PubMed ID: 34801029
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy and safety of anlotinib in 16 patients with advanced non-small cell lung cancer].
Si XY; Wang HP; Zhang XT; Wang MZ; Zhang L
Zhonghua Nei Ke Za Zhi; 2018 Nov; 57(11):830-834. PubMed ID: 30392239
[No Abstract] [Full Text] [Related]
9. Anlotinib as a post-third-line therapy for the treatment of advanced nonsmall cell lung cancer.
Li L; Liu W; Wang Y; Zhang Q; Chi C; Bai Q; Xu C; Yang R
J Chemother; 2021 Nov; 33(7):492-498. PubMed ID: 33818318
[TBL] [Abstract][Full Text] [Related]
10. Anlotinib, a novel TKI, as a third-line or further-line treatment in patients with advanced non-small cell lung cancer in China: A systemic review and meta-analysis of its efficacy and safety.
Ye H; Li Z; Liu K; Zhang F; Cheng Z
Medicine (Baltimore); 2021 Jun; 100(23):e25709. PubMed ID: 34114981
[TBL] [Abstract][Full Text] [Related]
11. Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: A multicenter, randomized phase II trial.
Pu X; Xiao Z; Li J; Wu Z; Ma Z; Weng J; Xiao M; Chen Y; Cao Y; Cao P; Wang Q; Xu Y; Li K; Chen B; Xu F; Liu L; Kong Y; Zhang H; Duan H; Wu L
Lung Cancer; 2024 May; 191():107538. PubMed ID: 38552544
[TBL] [Abstract][Full Text] [Related]
12. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial.
Han B; Li K; Wang Q; Zhang L; Shi J; Wang Z; Cheng Y; He J; Shi Y; Zhao Y; Yu H; Zhao Y; Chen W; Luo Y; Wu L; Wang X; Pirker R; Nan K; Jin F; Dong J; Li B; Sun Y
JAMA Oncol; 2018 Nov; 4(11):1569-1575. PubMed ID: 30098152
[TBL] [Abstract][Full Text] [Related]
13. Anlotinib-containing regimen for advanced small-cell lung cancer: A protocol of meta-analysis.
Yu G; Cai Q; Xu X; Shen Y; Xu K
PLoS One; 2021; 16(3):e0247494. PubMed ID: 33705427
[TBL] [Abstract][Full Text] [Related]
14. Apatinib in the treatment of advanced non-small-cell lung cancer: A meta-analysis.
Yu GC; Yang J; Ye B; Xu LL; Li XY; Zheng GR
Math Biosci Eng; 2019 Aug; 16(6):7659-7670. PubMed ID: 31698632
[No Abstract] [Full Text] [Related]
15. Effect of anlotinib as a third- or further-line therapy in advanced non-small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial.
Cheng Y; Han B; Li K; Wang Q; Zhang L; Shi J; Wang Z; He J; Shi Y; Chen W; Wang X; Luo Y; Nan K; Jin F; Li B; Zhu J
Cancer Med; 2020 Apr; 9(8):2621-2630. PubMed ID: 32064794
[TBL] [Abstract][Full Text] [Related]
16. Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial.
Zhou AP; Bai Y; Song Y; Luo H; Ren XB; Wang X; Shi B; Fu C; Cheng Y; Liu J; Qin S; Li J; Li H; Bai X; Ye D; Wang J; Ma J
Oncologist; 2019 Aug; 24(8):e702-e708. PubMed ID: 30902918
[TBL] [Abstract][Full Text] [Related]
17. Anlotinib Combined with S-1 in Third- or Later-Line Stage IV Non-Small Cell Lung Cancer Treatment: A Phase II Clinical Trial.
Xiang M; Yang X; Ren S; Du H; Geng L; Yuan L; Wen Y; Lin B; Li J; Zhang Y; Feng G; Du X
Oncologist; 2021 Dec; 26(12):e2130-e2135. PubMed ID: 34423518
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study.
Liu Z; Gao S; Zhu L; Wang J; Zhang P; Li P; Zhang F; Yao W
Cancer Med; 2021 Nov; 10(21):7593-7600. PubMed ID: 34564939
[TBL] [Abstract][Full Text] [Related]
19. Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer.
Si X; Zhang L; Wang H; Zhang X; Wang M; Han B; Li K; Wang Q; Shi J; Wang Z; Cheng Y; He J; Shi Y; Chen W; Wang X; Luo Y; Nan K; Jin F; Li B; Chen Y; Zhou J; Wang D
Lung Cancer; 2018 Aug; 122():32-37. PubMed ID: 30032842
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitors plus anlotinib versus anlotinib alone as third-line treatment in advanced non-small-cell lung cancer: a retrospective study.
Zhang W; Zhang C; Yang S; Chen Q; Wang C; Guo Q
Future Oncol; 2021 Nov; 17(31):4091-4099. PubMed ID: 34254526
[No Abstract] [Full Text] [Related]
[Next] [New Search]